Stock fact sheet · data as of

Longevity Health Holdings Inc. (XAGE): fair value, margin of safety and Wheel Score

Consumer Defensive · Household & Personal Products · United States · Speculative / Distressed

Close0.1120
GLS fair value71.781 of 9 models
Margin of safety+100%price below fair value
Wheel Score39No optionscapped: no options
Health3/9Piotroski F-score
Moat3.0/10GLS 10-year score
Market cap$277K1k shares a day
Implied vol.-no listed options
P/E-EPS -2.76
Dividend yieldnone
Beta0.43moves less than the market
Next earnings-no date recorded

Is XAGE undervalued?

XAGE has a margin of safety of 100%: the stock closed at 0.1120 on 16 Oct 2026 against a GLS average fair value of 71.78. 1 of the 1 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.

The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.

The nightly engine files XAGE under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for XAGE

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF71.78+63992%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-2.54-2367%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Longevity Health Holdings Inc. scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 3.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are high - ROIC 128.7%, ROE 117.7%, ROA -291.7% - with debt at -0.09 times equity and negative free cash flow.

Longevity Health Holdings Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 1/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score3 / 9ROIC128.7%
GLS Moat3.0 / 10ROE117.7%
Debt / equity-0.09ROA-291.7%
Free-cash-flow yield-888.6%Payout ratio0%
Institutions1 / 10Insiders · Congress10 · 5 / 10

Wheel Score 39: No options

No options are listed on Longevity Health Holdings Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.

Volume runs at 1k shares a day on a market cap of $277K, with a beta of 0.43 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value25 / 25100% margin of safety
Health7 / 20Piotroski 3/9
Moat5 / 15moat 3.0/10
Premium0 / 20no option data
Stability6 / 201k shares/day, $0M cap, beta 0.43

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

No upcoming earnings date is recorded for XAGE in the nightly calendar.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Household & Personal Products

The 12 companies below are the closest to Longevity Health Holdings Inc. by market cap within the Household & Personal Products industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
BIOT
Instinct Bio Technical Co. Holdings Inc.
0.2756--24No options$1M
SNBH
Sentient Brands Holdings Inc.
0.3447--30No options$2M
BYAH
Park Ha Biological Technology Co., Ltd. Ordinary Shares
2.39--29No options$2M
NASO
Naples Soap Company Inc.
1.15--25No options$3M
CAWW
CCA Industries, Inc.
0.4000--28No options$3M
TANH
Tantech Holdings Ltd
13.90751.78+98%39No options$9M
ADTI
Adapti, Inc.
1.56--27No options$13M
DSY
Big Tree Cloud Holdings Limited
3.31--27No options$16M
UG
United-Guardian, Inc.
6.977.65+9%39No options$32M
AXIL
Axil Brands, Inc.
5.5012.10+55%39No options$38M
GROV
Grove Collaborative Holdings, Inc.
0.99636.25+84%42Weak$43M
SLSN
Solesence, Inc. Common Stock
0.9503--30No options$67M

⚖ Compare XAGE with 7 of them   All Consumer Defensive stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about XAGE

Is XAGE undervalued right now?

By the GLS models, yes: at 0.1120 the stock is 100% below the average fair value of 71.78 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.

What is the Wheel Score of XAGE and what does it mean?

XAGE has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for XAGE?

71.78 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Longevity Health Holdings Inc. report earnings next?

No upcoming earnings date is recorded for XAGE in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.

Does XAGE have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on XAGE, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.